ATACAND HCT (candesartan cilexetil and hydrochlorothiazide) by ANI Pharmaceuticals is mechanism of action angiotensin ii is formed from angiotensin i in a reaction catalyzed by angiotensin-converting enzyme (ace, kininase ii). Approved for hypertension. First approved in 2000.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
ATACAND HCT is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) for oral treatment of hypertension. Candesartan selectively blocks AT1 receptors to prevent vasoconstriction and aldosterone secretion, while HCTZ reduces plasma volume through renal sodium and chloride excretion. The combination leverages complementary mechanisms to control blood pressure while offsetting the potassium-wasting effects of the diuretic.
Product is approaching loss of exclusivity with minimal recent spending ($609K in Part D claims, 2023), indicating a mature/declining brand with likely reduced team investment.
Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and…
Worked on ATACAND HCT at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Thiazide Diuretic
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moATACAND HCT is a mature, legacy antihypertensive combination with zero linked job opportunities in current recruitment. Working on this product offers minimal career growth potential given its LOE-approaching status, legacy positioning, and declining commercial focus under ANI Pharmaceuticals.